Capitol Perspectives
-
Trump Targets The Pharmaceutical Industry
2/1/2017
Our new President seemed to criticize recent inversions, but more importantly vowed to go after the industry: “Our drug industry has been disastrous.
-
Risks And Rewards Of Repeal And Replace
1/1/2017
The Republican sweep in the 2016 elections hands the enormous power of the Center for Medicare and Medicaid Innovation (CMMI) to the Trump administration. What to do with this power?
-
Washington Outlook For 2017: Trump Takes The Helm
12/1/2016
The stunning Trump victory and the Republican hold in the Senate, giving the GOP full control over the executive and legislative branches, provides some breathing space for a pharmaceutical industry that increasingly felt under siege.
-
Leaked Emails, Physician Reg Signal Risks For Rx Industry
11/1/2016
As the most bizarre and unpredictable election season draws to a close, scrutiny is turning to wikileaked emails among senior officials in the Clinton campaign licking their chops to take on the pharmaceutical industry, and healthcare policymaking by the executive branch.
-
Congress’ Abdication Of Authority Of Medicare To The Executive
10/1/2016
Six years after the enactment of the Affordable Care Act (ACA), policymakers are just beginning to appreciate a little-known provision that essentially outsources Congress’ authority over Medicare to the executive branch.
-
Rx Industry Vulnerable On Generic Delay In Fall
9/1/2016
There is growing chatter among congressional aides that the pharma industry should ante up some resources to help address some yet-unresolved healthcare issues.
-
If Government Fails, More Government!
8/1/2016
In June, the Obama administration’s Office of the Actuary issued the Medicare Trustees report, which determined “The Hospital Trust Fund is not adequately financed over the next 10 years.” The trust fund will be depleted by 2028, two years earlier than last year’s estimate.
-
Administration’s Response To Antibiotic Challenge Falls Far Short
7/1/2016
Even if we eliminated all use of antibiotics in animals and all unnecessary use in humans, we still are bound by a pathetic pipeline to combat what we’re facing now.
-
Congress Rebukes CMS On Part B Demo
6/1/2016
CMS has received dramatic and overwhelming rejection from Congress and stakeholders demanding the proposal be withdrawn or substantially modified.
-
An Interview With Stephen Ubl, President Of PhRMA
5/1/2016
Ubl talks about topics such as drug pricing, the industry’s approach to PBMs, and the political antipharmaceutical rhetoric.